SOPHiA, Myriad Partner on Prostate Cancer Companion Diagnostic Development
SOPHiA GENETICS and Myriad Genetics collaborate to develop a prostate cancer companion diagnostic using PrGIS, a biomarker for homologous recombination deficiency. Myriad's MyChoice CDx test, currently used in ovarian cancer, will be expanded for prostate cancer. The partnership aims to evaluate PrGIS in clinical trials and enable global laboratory testing. Myriad will present research at the European Society for Medical Oncology Congress 2026.
How this was made
The 30-second read
Why it matters
The deal expands both companies' precision oncology capabilities, potentially opening new revenue streams and enhancing market positioning in cancer diagnostics.
Market read
The collaboration could influence investor sentiment toward biotech diagnostic stocks and signal broader industry movement toward decentralized testing.
What to watch
Lack of disclosed funding amounts and timeline for clinical validation limits immediate impact.
Background
SOPHiA GENETICS and Myriad Genetics announced a collaboration to develop a prostate cancer-specific genomic instability score (PrGIS) as a companion diagnostic, with involvement from AstraZeneca and plans to present data at the ESMO Congress 2026.
Ticker impact
Myriad Genetics announced a collaboration with SOPHiA GENETICS to develop a prostate cancer companion diagnostic.
potential modest upside as market prices in partnership
No financial terms disclosed; impact depends on clinical validation progress.
SOPHiA GENETICS entered a partnership with Myriad Genetics to integrate PrGIS technology into a decentralized companion diagnostic.
possible modest upside as investors value expanded market footprint
Benefits hinge on successful clinical adoption; no monetary details provided.
Market effects
May boost the biotech diagnostic sector by highlighting precision oncology collaborations.
Both US and European markets could see slight interest in related stocks.
Reflects growing global focus on prostate cancer companion diagnostics.
Counterpoint
The partnership may not translate into near‑term revenue without disclosed financial terms.
Key entities
- companySOPHiA GENETICS
Swiss biotech firm providing a cloud‑based platform for genomic testing.
- companyMyriad Genetics
US‑listed genetics company developing diagnostic tests, ticker MYGN.
- companyAstraZeneca
Pharma partner referenced in the collaboration.
